CION Ameerpet
Immunotherapy uses the immune system, or lab-made antibodies, to find and destroy lymphoma cells. This guide explains monoclonal antibodies, anti-CD20 therapy and newer immune treatments — how they work, which lymphomas they suit, and the care CION delivers directly in Hyderabad.
Immunotherapy for lymphoma is a family of treatments that harness the immune system — or lab-made immune proteins — to identify and destroy lymphoma cells. Unlike chemotherapy, which works by attacking rapidly dividing cells throughout the body, immunotherapy is designed to be more precise: it aims at features that are concentrated on the cancer cell itself.
The most established and widely used form is the monoclonal antibody — a manufactured antibody built to recognise one specific marker on the surface of a lymphoma cell. Newer classes add to this toolkit: immune-checkpoint inhibitors that release the brakes on immune cells, bispecific antibodies that connect immune cells directly to the cancer, and cell-based therapies. Because these treatments depend on what the cancer looks like at a molecular level, accurate biopsy and marker testing come first.
This page explains the drug classes and how they work. It does not prescribe specific medicines — the exact agent and regimen are chosen by your oncology team and set out on our Lymphoma Treatment in Hyderabad page. For the full overview of the disease, start at the Lymphoma hub.
The arrival of the first anti-CD20 monoclonal antibody in the late 1990s is widely regarded as one of the biggest advances in lymphoma care. Adding an anti-CD20 antibody to chemotherapy improved survival in common B-cell lymphomas so substantially that antibody-plus-chemotherapy became the standard of care worldwide. (Source: outcomes summarised in NCCN and ESMO B-cell lymphoma guidelines; individual results vary.)
Each class works through a different mechanism. Which one suits you depends on your lymphoma subtype and the markers found on your biopsy — never on the name of a drug alone.
Lab-made antibodies that lock onto a surface marker — most often CD20 on B-cell lymphomas — and flag the cell for immune destruction. This is the backbone of most B-cell lymphoma treatment and is usually combined with chemotherapy. Learn more about the wider group on our targeted therapy for lymphoma page.
A monoclonal antibody joined to a chemotherapy payload. The antibody homes in on a marker such as CD30 (common in Hodgkin lymphoma and some T-cell lymphomas) and delivers the drug directly to the cancer cell, limiting exposure elsewhere.
These release natural "brakes" on immune T-cells so they can attack the cancer. They are particularly active in classic Hodgkin lymphoma and are used in selected relapsed or refractory situations — see the relapsed/refractory pathway.
The newest classes. Bispecific antibodies grab an immune cell with one arm and the lymphoma cell with the other. CAR T-cell therapy re-engineers a patient's own T-cells — coordinated through accredited partner facilities.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Want to know whether a monoclonal antibody or newer immunotherapy fits your lymphoma subtype? CION's haematology and medical oncology team can review your biopsy and PET-CT and explain your options.
Your immune system naturally makes antibodies — Y-shaped proteins that recognise and stick to foreign targets. A monoclonal antibody lymphoma treatment simply borrows that idea: scientists manufacture large quantities of one identical antibody, tuned to bind a single marker that sits on the surface of the lymphoma cell.
Once the antibody attaches, it can act in several ways: it can recruit immune cells and proteins to kill the marked cell, it can block a survival signal the cancer relies on, or — in an antibody-drug conjugate — it can deliver an attached chemotherapy payload directly into the cell. Because the target marker is far more concentrated on lymphoma cells than on most healthy tissue, this approach is generally gentler than chemotherapy given alone.
Antibodies are given by intravenous infusion, usually over cycles that align with chemotherapy. For most B-cell lymphomas the antibody is added to chemotherapy; in some settings it is used for maintenance therapy to keep a remission going. What an infusion day feels like is covered on our what to expect during an infusion page.
The marker on your lymphoma — found by immunohistochemistry on the biopsy — decides which antibody-based approach is even possible. Marker names are testing concepts; they are not drug names.
| Marker | Where it is common | Antibody approach |
|---|---|---|
| CD20 | Most B-cell non-Hodgkin lymphomas | Anti-CD20 monoclonal antibody (often with chemotherapy) |
| CD30 | Classic Hodgkin lymphoma; some T-cell lymphomas | Antibody-drug conjugate targeting CD30 |
| PD-L1 pathway | Classic Hodgkin lymphoma | Immune-checkpoint inhibitor |
| CD19 / CD3 | B-cell lymphomas (relapsed / refractory) | Bispecific antibody or CAR T-cell therapy (coordinated externally) |
This table is a general guide and does not name specific medicines. The actual agent, dose and schedule are decided by your treating team based on subtype, stage and fitness, following NCCN and ESMO guidance.
Because immunotherapy targets a marker on the cancer, the biopsy has to be read for those markers before treatment is chosen. Both NCCN and ESMO lymphoma guidelines make immunohistochemistry — testing for markers such as CD20 and CD30 — a routine part of diagnosis, precisely so that antibody-based therapy can be matched to the right patient. This is why CION confirms the subtype and markers at a tumour board before any antibody plan is recommended.
Anti-CD20 therapy is the most widely used immunotherapy in lymphoma. CD20 is a protein found on the surface of most B-cells — including the malignant B-cells that make up the majority of non-Hodgkin lymphomas. Crucially, CD20 is not present on the blood-forming stem cells, so an anti-CD20 monoclonal antibody can strip out B-cells (healthy and cancerous) while leaving the body able to regenerate its blood supply afterwards.
In most common B-cell lymphomas, the antibody is combined with alkylating and other chemotherapy classes; the two together consistently outperform chemotherapy alone. In slow-growing (indolent) lymphomas, an anti-CD20 antibody may also be continued as maintenance therapy in follicular lymphoma to prolong remission. Because it depletes normal B-cells too, infection precautions and vaccination review are part of the plan.
CION delivers anti-CD20 antibody therapy directly, in a monitored infusion setting. To understand where it sits in the overall pathway, read our Lymphoma Treatment in Hyderabad page or meet the best lymphoma doctors in Hyderabad.
Immunotherapy is often better tolerated than chemotherapy, but each class has its own profile that the team watches for:
CION monitors and manages these directly, and coordinates supportive care such as an infusion port or central line where repeated infusions are planned. Response is reassessed with PET-CT during and after treatment.
Adding antibody-based immunotherapy to treatment has meaningfully improved lymphoma outcomes over the past two decades. Exact figures depend heavily on the subtype, stage, age and fitness, so they should be read as broad reference ranges, not promises.
For context, published series report that Hodgkin lymphoma — where checkpoint inhibitors and CD30-directed antibodies are now part of care — has around an 80–90% long-term survival in many groups, while diffuse large B-cell lymphoma (DLBCL), treated with anti-CD20 antibody plus chemotherapy, is often reported around 60–70% (per outcomes summarised in NCCN and ESMO guidelines). These are population figures; results vary by individual, and relapsed or refractory disease follows a different pathway. Your own likely outlook should be discussed with your treating oncologist.
Where standard immunotherapy stops working, options such as clinical trials, bispecific antibodies and CAR T-cell therapy may be considered.
CION delivers monoclonal antibody therapy, immunotherapy infusions, chemotherapy and targeted therapy directly, in a monitored day-care infusion unit with pre-medication and infusion-reaction protocols. The pathway is deliberately marker-led:
A dedicated CION leukaemia and blood cancer service supports related diagnoses. To review your report, request a free second opinion or call 18002028726.
As a pillar page on lymphoma treatments, this guide links to every companion page in the cluster. Use these to go deeper on a specific therapy:
Get a free written second opinion from CION's lymphoma tumour board — especially valuable before starting, or switching, an antibody-based or immunotherapy plan.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Immunotherapy for lymphoma is a group of treatments that use the immune system — or lab-made immune proteins — to find and destroy lymphoma cells, rather than poisoning fast-dividing cells the way chemotherapy does. The most established form is the monoclonal antibody: a manufactured antibody engineered to lock onto a specific marker on the surface of the lymphoma cell and flag it for immune attack. Other immunotherapy classes include immune-checkpoint inhibitors, bispecific antibodies and cell-based therapies. Which class fits depends on the lymphoma subtype and the markers found on the tumour. For the full plan, see our Lymphoma Treatment in Hyderabad page.
A monoclonal antibody is a laboratory-made copy of a single type of antibody, designed to recognise one specific target. In lymphoma, the antibody is built to bind a protein marker on the surface of the malignant B-cell or T-cell. Once attached, it can flag the cell for destruction by the immune system, block a signal the cell needs to survive, or — in newer designs — carry a payload directly to the cell. Because it targets a marker that is concentrated on lymphoma cells, a monoclonal antibody spares many healthy tissues. Antibodies are usually given by infusion, and are often combined with chemotherapy. The exact regimen is set by your oncology team; discuss it on our Treatment page.
Anti-CD20 therapy uses a monoclonal antibody aimed at CD20 — a protein found on the surface of most B-cell lymphomas. Because CD20 sits on the malignant B-cells (and normal B-cells) but not on stem cells or most other tissues, an anti-CD20 monoclonal antibody can target the lymphoma while sparing the body's ability to regenerate blood cells. This class transformed B-cell lymphoma care and is one of the most widely used immunotherapies in the disease, frequently paired with chemotherapy. Whether it suits you depends on confirming CD20 on your biopsy. We do not name specific drug brands here — your oncologist will match the exact agent to your subtype. Learn about the broader plan on our Lymphoma Treatment page.
Not usually — for most lymphomas, monoclonal antibodies are given together with chemotherapy rather than instead of it, because the two work in different, complementary ways. The antibody marks lymphoma cells for immune destruction while chemotherapy attacks dividing cells, and the combination tends to work better than either alone. In some situations — such as maintenance treatment after remission, or in older or frailer patients — antibody-based therapy may be used with lighter chemotherapy or on its own. Newer immunotherapy classes are also used when standard treatment stops working. The right balance is decided by your lymphoma subtype, stage and fitness at CION's tumour board.
Most B-cell lymphomas — which make up the large majority of non-Hodgkin lymphomas — carry the CD20 marker and respond to anti-CD20 monoclonal antibody therapy. Classic Hodgkin lymphoma cells typically carry a different marker (CD30), which is targeted by a separate antibody-based approach, and Hodgkin lymphoma is also sensitive to immune-checkpoint inhibitors. Some T-cell lymphomas and certain subtypes have their own suitable targets. The deciding factor is what the biopsy and immunohistochemistry show — the markers on your specific tumour. This is why accurate pathology and marker testing come first. For subtype detail, start at the Lymphoma hub.
Monoclonal antibodies are generally better tolerated than chemotherapy, but they are not side-effect-free. The most common issue is an infusion reaction — chills, fever, flushing or breathlessness during or soon after the drip — which is why the first infusions are given slowly under close monitoring and with pre-medication. Because anti-CD20 therapy also lowers normal B-cells, it can increase infection risk for a time, so vaccination status and infection precautions are reviewed. Checkpoint inhibitors carry a different profile of immune-related effects. CION monitors and manages these directly. For the wider picture of treatment side effects, see managing lymphoma chemotherapy side effects and what to expect during an infusion.
Yes. Monoclonal antibody therapy, immunotherapy infusions, chemotherapy and targeted therapy are delivered directly at CION in Hyderabad, in a monitored day-care infusion setting with pre-medication and reaction protocols in place. Every case is first reviewed by a multidisciplinary tumour board that confirms the subtype and markers before recommending an antibody-based plan. Where a treatment such as CAR T-cell therapy or a stem-cell transplant is indicated, CION coordinates that step through accredited partner facilities and manages the surrounding care. To discuss your report, book a free consultation or call 1800 202 8726.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.